Stock Market Cafe
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Stock Market Cafe
No Result
View All Result
Home Trading News

Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs

by
November 5, 2021
in Trading News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Stripe tells employees it will decide on an IPO within the next year

The rally that won’t quit says it’s not all about the Fed — listen to Thursday’s ‘Homestretch’

British artificial intelligence scientist and entrepreneur Demis Hassabis.

OLI SCARFF | AFP | Getty Images

Google parent company Alphabet has launched a new drug discovery company in the U.K. called Isomorphic Labs.

The company will build on research carried out by London artificial intelligence lab DeepMind, which Google acquired in 2014. While the firm was only officially announced on Thursday, it was incorporated in February, according to a filing with Companies House, the U.K. company registry.

Demis Hassabis, the CEO and co-founder of DeepMind, is also the founder and CEO of Isomorphic Labs. He will remain CEO of DeepMind.

In a blog post, Hassabis described Isomorphic Labs as a commercial venture with a mission to “reimagine the entire drug discovery process from the ground up.”

A spokesperson for Isomorphic Labs stressed that the company is separate from DeepMind and that it has its own dedicated resources. They stopped short, however, of saying how many staff or how much capital it has at its disposal.

“Where relevant, teams from both companies may collaborate, especially in the early days as Isomorphic Labs is hiring its team,” the spokesperson said.

Isomorphic Labs plans to use artificial intelligence software to create new drugs and medicines.

Identifying new drugs is a long, complex trial-and-error process that involves combining lots of different compounds in different ways. Several companies including London’s BenevolentAI and San Francisco’s Atomwise believe that AI can speed up the process.

“We believe that the foundational use of cutting edge computational and AI methods can help scientists take their work to the next level, and massively accelerate the drug discovery process,” wrote Hassabis, a former child chess prodigy with degrees in computer science and cognitive neuroscience from Cambridge and University College London, respectively.

“AI methods will increasingly be used not just for analyzing data, but to also build powerful predictive and generative models of complex biological phenomena,” he added.

Alphabet has several other companies working on health care including Verily, which is developing software for the health care sector, and Calico, which is working on ageing and extending the human life.

DeepMind has also worked on health care, and it used to have its own dedicated DeepMind Health division. However, this was absorbed by Google in 2018 after a controversial deal with Britain’s National Health Service.

Since then, DeepMind has pursued research in other areas of life science and it has made breakthroughs in a field known as protein folding. Last year, the company announced that it had developed an AI system that can accurately predict the structure that proteins will fold into in a matter of days, solving a 50-year-old “grand challenge.”

ShareTweetPin

Related Posts

Stripe tells employees it will decide on an IPO within the next year

by
January 26, 2023
0

Stripe co-founder and CEO, Patrick Collison Manuel Blondeau | Getty Images Stripe, the fintech company once valued at $95 billion...

The rally that won’t quit says it’s not all about the Fed — listen to Thursday’s ‘Homestretch’

by
January 26, 2023
0

Jim Cramer says that people just seem to want to own stocks this year. More soft-landing hopes after morning economic...

Tesla’s bounce on quarterly results can teach us something about mega-cap growth names

by
January 26, 2023
0

This is the daily notebook of Mike Santoli, CNBC's senior markets commentator, with ideas about trends, stocks and market statistics....

NBCUniversal expects Peacock losses to peak this year as streamer slowly adds subscribers

by
January 26, 2023
0

In this article CMCSA Follow your favorite stocksCREATE FREE ACCOUNT The NBCUniversal Inc. Peacock streaming service is displayed on a...

Microsoft’s AI push has some analysts raving about the stock even after lackluster earnings

by
January 26, 2023
0

Microsoft 's earnings report earlier this week was largely considered dissatisfying to analysts. But the tech giant's focus on artificial...

Next Post

Stocks making the biggest moves premarket: Pfizer, Canada Goose, Live Nation and more

Peloton shares collapse as momentum for its at-home fitness equipment slows

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Crocs sees fourth-quarter sales up 42%, CEO Andrew Rees says 2021 was ‘exceptional year’

    0 shares
    Share 0 Tweet 0
  • Biden didn’t accept Putin’s ‘red lines’ on Ukraine – here’s what that means

    0 shares
    Share 0 Tweet 0
  • Buying a car from the factory sounds expensive, but it can actually save you money. Here’s how to do it.

    0 shares
    Share 0 Tweet 0
  • The states that won’t tax military retirement in 2022

    0 shares
    Share 0 Tweet 0
  • Roth TSP vs. Roth IRA: How Do They Compare?

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.stockmarket-cafe.com
No Result
View All Result
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy

All rights reserved by www.stockmarket-cafe.com